tbuckley/cabot-search huggingface dataset:
A multicenter study on the prevalence of resistance to broad-spectrum cephalosporins among Enterobacteriaceae in Italy. J. Clinical Microbiology and Infection
Authors: Gaetano Pierpaolo Privitera, E Magliano, Gc Schito, G Ortisi, F Vegni, E Conte, F. Marchetti
Journal: Clinical Microbiology and Infection (1997)
Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
Authors: R. C. Whorf, J. D. Hainsworth, D. R. Spigel, D. A. Yardley, H. A. Burris, D. M. Waterhouse, E. R. Vazquez, F. A. Greco
Journal: Journal of Clinical Oncology (2008)

5010 Background: Recent use of anti-angiogenesis agents and m-TOR inhibitors has improved the treatment of patients (pts) with advanced RCC. In this multicenter phase II trial, we evaluated the efficacy and safety of a combination of bevacizumab (VEGF inhibitor) and RAD001 (m-TOR inhibitor) in pts with metastatic RCC. Methods: Pts with metastatic or unresectable locally recurrent clear cell RCC, ECOG PS 0 or 1, were eligible. 2 groups of pts were enrolled, based on previous treatment: Group A, no previous treatment with sorafenib or sunitinib; Group B, previous treatment with sorafenib and/or sunitinib. All pts received bevacizumab 10mg/kg IV every 2 weeks and RAD001 10mg PO daily. Pts were reevaluated after 8 weeks of treatment; pts with objective response/stable disease continued treatment with reevaluations every 8 weeks until progression. Results: Between July 2006 and November 2007, 59 pts (30 Group A, 29 Group B) were enrolled. The median age was 65 years; 76% had intermediate Motzer prognostic scores, and 43 pts (73%) had undergone previous nephrectomy. 42 pts (71%) received at least 8 weeks of treatment and were reevaluated; 6 pts were inevaluable (toxicity, 4; rapid progression, 1; intercurrent illness) and 11 are too early. 90% of pts who completed 8 weeks of treatment had objective response (21%) or minor response/stable disease (69%). Efficacy in Groups A and B is compared in the table below. Grade 3/4 proteinuria occurred in 10 pts (19%); other grade 3/4 toxicity was uncommon (fatigue 9%, stomatitis 8%). Grade 1/2 toxicities were common including fatigue (68%), skin rash/pruritus (55%), mucositis/stomatitis (49%), hyperlipidemia (45%), nausea (40%), hypertension (25%). Conclusions: The combination of bevacizumab + RAD001 is active and tolerable treatment for metastatic clear cell RCC. The combination has activity in pts previously treated with sorafenib and/or sunitinib. Better definition of the efficacy of this combination versus single-agent therapy requires comparative trials. Efficacy in Groups A and B Group A (N=30) Group B (N=18) Partial response 7 (23%) 2 (11%) Minor response (tumor reduction 10–30%) 13 (43%) 5 (28%) Stable 3 (10%) 8 (44%) Progression 2 (7%) 2 (11%) Unevaluable 5 (17%) 1 (6%) Median PFS 9 months 6 months Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bayer, Genentech, Novartis Genentech, Novartis Bristol-Myers Squibb, Eli Lilly and Company, Genentech, GlaxoSmithKline, GPC Biotech, Novartis, sanofi-aventis
Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041)
Authors: H. Nomura, D. Aoki, F. Takahashi, N. Katsumata, Y. Watanabe, I. Konishi, T. Jobo, M. Hatae, M. Hiura, N. Yaegashi
Journal: Journal of Clinical Oncology (2008)

16526 Background: The purpose of this study is to assess the efficacy and safety of treatment with taxane plus platinum in combination therapies for advanced or recurrent endometrial carcinoma. Methods: The study planned to administer docetaxel (70 mg/m2) plus cisplatin (60 mg/m2) (DP), docetaxel (60 mg/m2) plus carboplatin (AUC 6) (DC), or paclitaxel (180 mg/m2) plus carboplatin (AUC 6) (TC) every 3 weeks until disease progression or adverse effects prohibited further therapy. Eligibility criteria of this study allowed for entry of patients with measurable disease derived from histologically confirmed stage III/IV or recurrent endometrial carcinoma and/or patients having had a treatment-free interval following cytotoxic chemotherapy, radiotherapy, or hormonal therapy of at least 6 months, 4 weeks or 2 weeks, respectively. Among these regimens the study compared the tumor response rate as the primary endpoint as well as toxicity. An independent review committee assessed the tumor response for each patient according to RECIST. Results: Ninety patients were enrolled. Of the enrolled patients, 88 were eligible and consequently 29, 29, and 30 patients were randomly assigned to DP, DC, and TC, respectively. Regarding the frequency of the main toxicities, the following were observed: grade 3 and 4 neutropenia in 83.3, 90.0, and 76.6%; febrile neutropenia in 10.0, 6.7, and 3.3%; thrombocytopenia in 6.7, 10.0, and 10.0%; diarrhea in 13.3, 3.3, and 0%, respectively; and grade 2 neurotoxicity in 13.3% of TC group. These toxicity profiles were not significantly different; however, diarrhea and neurotoxicity tended to be more frequent in DP and TC, respectively. Tumor response rates were 51.7% (0 CR, 15 PR; 95% C.I.; 32.5–70.6), 48.3% (4 CR, 10 PR; 29.4–67.5), and 60.0% (2 CR, 16 PR; 40.6–77.3) in DP, DC, and TC, respectively (P = 0.65). Conclusions: Toxicity of taxane plus platinum combination therapies was confirmed to be tolerable. The efficacy was similar in each arm and their potential efficacy will allow us to choose an experimental arm for a phase III trial to confirm a survival benefit of taxane plus platinum for endometrial carcinoma. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Bristol-Myers Squibb, Kyowa Hakko Kogyo, Nippon Kayaku, Pfizer Japan, sanofi-aventis
Transmission of Zika Virus Through Sexual Contact with Travelers to Areas of Ongoing Transmission — Continental United States, 2016
Authors: Susan L. Hills, Kate Russell, Morgan Hennessey, Charnetta Williams, Alexandra M. Oster, Marc Fischer, Paul Mead
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Zika virus is a flavivirus closely related to dengue, West Nile, and yellow fever viruses. Although spread is primarily by Aedes species mosquitoes, two instances of sexual transmission of Zika virus have been reported, and replicative virus has been isolated from semen of one man with hematospermia. On February 5, 2016, CDC published recommendations for preventing sexual transmission of Zika virus. Updated prevention guidelines were published on February 23. During February 6-22, 2016, CDC received reports of 14 instances of suspected sexual transmission of Zika virus. Among these, two laboratory-confirmed cases and four probable cases of Zika virus disease have been identified among women whose only known risk factor was sexual contact with a symptomatic male partner with recent travel to an area with ongoing Zika virus transmission. Two instances have been excluded based on additional information, and six others are still under investigation. State, territorial, and local public health departments, clinicians, and the public should be aware of current recommendations for preventing sexual transmission of Zika virus, particularly to pregnant women. Men who reside in or have traveled to an area of ongoing Zika virus transmission and have a pregnant partner should abstain from sexual activity or consistently and correctly use condoms during sex with their pregnant partner for the duration of the pregnancy.
Abstract 18410: Association Between Serum Uric Acid Level and the Presence of Coronary Vulnerable Plaques
Authors: Taizo Kimura, Akira Sato, Toru Adachi, Eiji Ojima, Hiroaki Watabe, Yuki Kakefuda, Yoshihiro Seo, Kazutaka Aonuma
Journal: Circulation (2012)

Background: Uric acid may have effects on vascular remodeling and atherosclerosis. The purpose of this study was to evaluate the relationship between serum uric acid (SUA) levels and presence of coronary vulnerable plaque assessed by computed tomography angiography (CTA). Method: Five hundred twenty-nine patients with suspected coronary artery disease (CAD) underwent 64-slice CTA to evaluate the prevalence of CAD and plaque morphology. Coronary vulnerable plaque was defined as positive vessel remodeling (PR) (RI&gt;1.1) and low-attenuation plaques (LAP) (&lt;50 Hounsfield Unites). SUA level was divides into 4 groups: &lt;5, 5 to &lt;6, 6 to &lt;6.8, ≧6.8 mg/dl. Results: The higher SUA levels were associated with the higher prevalence of coronary vulnerable plaque (P&lt;0.001).The number of vulnerable plaques per patient was significantly higher in patients with higher SUA levels (Figure, P=0.002). In multivariate logistic analysis that adjusted for age, gender, smoking, hypertension, dyslipidemia, diabetes mellitus and estimated glomerular filtration rate, the patients whose SUA level 5 to &lt;6mg/dl, 6 to &lt;6.8mg/dl, and ≧6.8mg/dl had odds ratio (OR) of 1.194 (95% CI: 0.773-2.078, P=0.525), 1.306 (95% CI: 0.085-2.510, P=0.382), 2.622 (95% CI: 1.643-4.541, P=0.002) respectively, for prediction of coronary vulnerable plaque, compared with those whose SUA level was &lt;5 mg/dl. Conclusion: SUA level was associated with the presence of coronary vulnerable plaques. Assessment of SUA level may be useful to identify the high risk patients with suspected CAD, and SUA may have a pathophysiologic effect on atherosclerosis.
A prospective analysis of 24 episodes of neuroleptic malignant syndrome
Authors: P Rosebush, T Stewart
Journal: American Journal of Psychiatry (1989)

The authors prospectively studied 24 consecutive cases of neuroleptic malignant syndrome occurring in 20 patients in a general hospital over a 6-year period. They present detailed data concerning the clinical setting in which neuroleptic malignant syndrome occurs, the associated clinical and laboratory features, the favorable outcome that can be achieved with vigorous supportive therapy, and the factors that might help predict whether patients with neuroleptic malignant syndrome will subsequently be able to tolerate the reintroduction of neuroleptic medication.
Host gene expression classifiers diagnose acute respiratory illness etiology
Authors: Ephraim L. Tsalik, Ricardo Henao, Marshall Nichols, Thomas Burke, Emily R. Ko, Micah T. McClain, Lori L. Hudson, Anna Mazur, Debra H. Freeman, Tim Veldman, Raymond J. Langley, Eugenia B. Quackenbush, Seth W. Glickman, Charles B. Cairns, Anja K. Jaehne, Emanuel P. Rivers, Ronny M. Otero, Aimee K. Zaas, Stephen F. Kingsmore, Joseph Lucas, Vance G. Fowler, Lawrence Carin, Geoffrey S. Ginsburg, Christopher W. Woods
Journal: Science Translational Medicine (2016)

Pathogen-specific host gene expression changes may combat inappropriate antibiotic use and emerging antibiotic resistance.
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
Authors: K M Kortuem, E Braggio, L Bruins, S Barrio, C S Shi, Y X Zhu, R Tibes, D Viswanatha, P Votruba, G Ahmann, R Fonseca, P Jedlowski, I Schlam, S Kumar, P L Bergsagel, A K Stewart
Journal: Blood Cancer Journal (2016)

Abstract We employed a customized Multiple Myeloma (MM)-specific Mutation Panel (M 3 P) to screen a homogenous cohort of 142 untreated MM patients for relevant mutations in a selection of disease-specific genes. M 3 Pv2.0 includes 77 genes selected for being either actionable targets, potentially related to drug–response or part of known key pathways in MM biology. We identified mutations in potentially actionable genes in 49% of patients and provided prognostic evidence of STAT3 mutations. This panel may serve as a practical alternative to more comprehensive sequencing approaches, providing genomic information in a timely and cost-effective manner, thus allowing clinically oriented variant screening in MM.
Impact of revised lymph node measurement rules in the new RECIST version 1.1 on the tumor response evaluation in patients with advanced lung cancer
Authors: M. Endo, H. Watanabe, S. Yamamoto, N. Yamamoto, Y. Ohe, T. Tamura
Journal: Journal of Clinical Oncology (2009)

7567 Background: The new RECIST ver. 1.1 was published in a special edition of the European Journal of Cancer in the first quarter of 2009 (EJC 2009;45:228). The major change involves the rules for lymph node measurement, which is to measure SHORT axis in stead of the longest diameter of lymph node. To be considered pathologically enlarged and measurable, a size of lymph node must be at least 15mm in short axis when assessed by CT scan. Lymph nodes that are at least 10mm but less than 15mm in short axis may be pathologic and can be considered as non-measurable/non-target lesions (not measured). The purpose of our study was to evaluate the response assessment using RECIST ver. 1.1. in comparison with that using ver. 1.0 in patients with advanced lung cancer. Methods: Two radiologists independently reviewed the objective tumour response of 305 patients (pts) with advanced lung cancer who had primary lesion and lymph node metastases as target lesions measured more than 10 mm in the longest diameter. According to ver. 1.1, only the short axis will be measured both at baseline and at follow-up. The response rates were calculated according to both the versions of RECIST. The tumor responses were divided into four categories (CR, PR, SD, PD), following proportion of agreement and estimation of kappa statistics between two the criteria as agreement measure. Results: The best overall responses as assessed by RECIST ver. 1.0 and ver. 1.1 are shown in the table. Out of the 108 pts with PR by ver.1.0, 8.3 % were downgraded to SD and 1.0 % was categorized as PD by ver.1.1. On the other hand, out of the 190 pts with SD by ver.1.0, 6.3 % were upgraded to PR and 8.9 % were downgraded to PD by ver.1.1. The proportion of agreement was 86.2 % (263/305, 95% CI: 75.8 - 96.6) and the kappa coefficient was 0.734 (95% CI: 0.662 - 0.806). Conclusions: No significant impact was observed for the revised lymph node measurement rules in the new RECIST ver. 1.1 on the response evaluation in pts with advanced lung cancer registered in this analysis. [Table: see text] [Table: see text]
The Influence Of Anti-HLA Antibodies On Engraftment and Donor’s Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Mismatched Unrelated Donors
Authors: Miroslaw Markiewicz, Anna Koclega, Sylwia Mizia, Urszula Siekiera, Alicja Dobrowolska, Monika Dzierzak-Mietla, Patrycja Zielinska, Krzysztof Bialas, Slawomira Kyrcz-Krzemien
Journal: Blood (2013)
EVA is an acceptable alternative to ABVD in patients with advanced Hodgkin’s and compromised pulmonary function: 8-year follow up
Authors: M. Salimichokami, S. Aminian, M. Bannazadeh, M. Shahzadi, M. Zamanian
Journal: Journal of Clinical Oncology (2005)

6683 ABVD is the standard treatment of advanced Hodgkin’s disease(HD). However two of the components,Bleomycin and DTIC have significant toxcicities such as lung fibrosis and emesis,and also uncertain single agent activity. The EVA regimen (VP16,Vinblastine and Doxurubicin) is an attempt to substitute a known active agent ie:VP16 for Bleo and DTIC. A series of 26 pts with advanced HD and a history of prior lung disease or radiation treatment were selected for this study. They included 7 stage2/bulky mediastinal tumors and all received consolidation XRT. The remaining pts recieved EVA only. The median F/U was 108n months. EVA: Etoposide 100mg/m2 days 1–3,VBL 6mg/m2 day-1 and Doxurubicin 50mg/m2 day-1. All drugs given iv. Cycles repeated Q.3 wk x 6 cycles. Results: Complete response(CR) was achieved in 25/26(96%). Of these 25 responders 8 pts relapsed in a median of 10 months(range 3–22). In F/U 17/26 pts had no evidence of recurrent HD, resulting in progression-free survival for the entire group of 65% at 108 mo. Five of the 8 relapsers achieved a 2nd-CR and were alive and disease-free at F/U at 108 mo. In the entire series 4 pts(15%) died of HD (one patient was induction failure and 3 pts relapsed post 1st CR). 22/26(85%) of pts continued free of disease. There was no pulmonary toxicity. Toxicities in general was comparable to ABVD. Conclusion: The EVA regimen has an overall survival comparable to standard ABVD in our study with the added advantage of lacking lung toxicity in this susceptible group of pts. No significant financial relationships to disclose.
Effect of FLT3 Ligand and Granulocyte Colony-Stimulating Factor on Expansion and Mobilization of Facilitating Cells and Hematopoietic Stem Cells in Mice: Kinetics and Repopulating Potential
Authors: Michael Neipp, Tatiana Zorina, Michele A. Domenick, Beate G. Exner, Suzanne T. Ildstad
Journal: Blood (1998)
Abstract 11185: Hypoxic Responses of M1 Macrophages are Critical for the Regulation of Cardiac Fibrosis
Authors: Hajime Abe, Norihiko Takeda, Hiroaki Semba, Soma Katura, Ichiro Manabe, Ryozo Nagai
Journal: Circulation (2012)

Hypoxia is a pathological condition in which the tissue is deprived of adequate oxygen supply. It occurs in myocardial ischemia and cardiac hypertrophy, and accelerates the inflammatory processes i...
Mesothelioma: Incidence and survival rates in Nova Scotia, Canada 1990–2002
Authors: S. F. Husain, W. Morzycki, R. Dewar, D. Rayson
Journal: Journal of Clinical Oncology (2005)

9636 Background: This study was conducted to evaluate the incidence and survival rates for mesothelioma in the province of Nova Scotia (NS), Canada using population-based data. Methods: A retrospective chart review was performed, using NS cancer registry data and cancer centre patient charts of all documented cases of mesothelioma in the province of NS between 1990 and 2002. Results: Between 1990 and 2002, 101 cases of mesothelioma were recorded. The overall incidence of mesothelioma was 1.3 per 100,000. The incidence rate by gender showed a higher rate in men than women with 1.47 per 100,000 versus 0.2 per 100,000, respectively. Incidence rates were highest in the area of Halifax County. The median age at the time of diagnosis was 70 in men and 64 in women. The distribution of mesothelioma per anatomical site was 87% pleural, 12% peritoneal and 1% unspecified. The most common presenting symptoms were shortness of breath (61%), chest pain (43%), and cough (27%). 69% of patients had documented asbestos exposure and 78% had a positive smoking history. The two year overall survival rate was 10% (10% for men and 15% for women). Conclusions: In Nova Scotia, Canada, the highest incidence of mesothelioma occurred in geographic areas where shipyards were common (Halifax County). Pleural disease was the most common anatomical site of origin for both genders. Men were at higher risk compared to women for the development of pleural mesothelioma over the time interval studied. Variable rates of mesothelioma were observed during the period examined. No significant financial relationships to disclose.
Health related quality of life and its effect on lung function
Authors: Marie Waatevik, Amund Gulsvik, Ernst Omenaas, Per Bakke, Ane Johannessen
Journal: European Respiratory Journal (2011)

Background:  SF-12 is a validated questionnaire for measuring patient-reported functional health and well-being. There is a paucity of knowledge on whether the physical component scale, PCS, part of the SF-12, could predict lung function longitudinally.   Methods:  In the Hordaland County Cohort Study, 1527 subjects, 52% men, aged 26-82 years at baseline performed post bronchodilator spirometry in 1996-97 and in 2003-2005. SF-12 was used as measurement of health related quality of life and PCS score was main predictor. We performed linear regression analyses of PCS and post BD FEV1 in 2003-05, and adjusted for sex, age, height, educational level, occupational exposure, smoking habits, packyears and baseline FEV1.   Results:  Mean FEV1 in 2003-2005 was 3.11L (SD 0.9). Mean baseline FEV1 was 3.46 L (SD 0.9), and mean PCS score of the SF 12 was 50.4 (SD 8.4). Coefficients (95% CI) for significant predictors in the multivariate model were; -0.03 (-0.03, -0.027) for age, 0.089 (0.02, 0.16 for ex smokers vs never smokers, 0.025 (-0.05, 0.1) for current smokers vs never smokers, 0.43 (0.36, 0.50) for men vs women, 0.14 (0.07, 0.21) for intermediate vs lower education, 0.14 (0.06, 0.23) for higher vs lower education, -0.01 (-0.02, -0.01) for packyears and 0.008 (0.005, 0.011) for PCS sum score. PCS was a significant risk factor for lower FEV1, but the significance did not remain when adjusting for baseline FEV1.   Conclusion:  The physical sum score of the SF-12 predicts lower lung function at follow up, but the effect did not remain after adjusting for baseline lung function.  However, this result shows that in absence of spirometry, SF-12 may serve as a simple and effective tool to identify persons at risk of COPD.
XPD 751 polymorphism customized second-line treatment with gemcitabine (G) or irinotecan (I) in advanced non-small cell lung cancer (NCSLC) patients (p)
Authors: C. Camps, R. de las Penas, G. Alonso, M. Provencio, J. Terrasa, G. Lopez Vivanco, A. Artal, R. Garcia Gomez, E. Pujol, J. M. Sanchez
Journal: Journal of Clinical Oncology (2005)

7191 Background: The XPD751 polymorphism is associated with DNA repair capacity. G has been shown to be active in NSCLC p with the Lys/Gln genotype while p with Lys/Lys or Gln/Gln could benefit more from a different chemotherapy regimen. In order to test the activity of customized chemotherapy based on XPD751 genotype in the second-line setting, NSCLC p were assigned to receive G (Lys/Gln) or I (Lys/Lys and Gln/Gln). Methods: NSCLC p who had progressed after first-line cisplatin/docetaxel. Inclusion criteria included histologically confirmed NSCLC, stage IIIB/ IV, age < 18, adequate renal, hepatic and bone marrow functions. p with Lys/Gln genotype received G 1200 mg/m2 days 1 and 8, every 21 days. p with Lys/Lys or Gln/Gln received I 250 mg/m2 day 1, every 21 days. Results: 88 p were analyzed (G 42, I 46): age, 60 years (range 31–77); males 88%; ECOG PS 0, 27.4%, 1, 72.6%; adenocarcinomas 45%, squamous cell 36.3%, large cell 13.8%, other 5%. XPD frequencies: Gln/Gln 14.8%, Lys/Gln 47.7%, Lys/Lys 37.5%. A total of 169 cycles of G and 136 of I have been administered: median 4.0 (range 1–17) and 3.0 (range 1–11), respectively. Overall response rate (ORR) for 68 evaluable p: 7.4%. ORR for 32 evaluable p in G: 15.6% (95% CI, 3.0–28.2%); 0 CR, 5 PR, 10 SD and 17 PD; 10 non-evaluable (6 p still on treatment, 4 early withdrawals). For 36 evaluable p in I: 0 CR, 0 PR, 10 SD, 26 PD; 10 non-evaluable (4 p still on treatment, 6 early withdrawals. Time to progression: 3.4 months (m) (95% CI, 2.4–4.3) for G, and 1.8 m (95% CI, 1.3–2.3) (P=0.0149). Median survival: 5.8 m (95% CI, 3.7–7.8) for G, and 4.5 months (95% CI, 3.2–5.9) for I (P=0.0482). Conclusions: XPD Lys/Gln polymorphism confers a good prognosis with G for refractory NSCLC p, whereas p with XPD Lys/Lys and Gln/Gln genotype have an intermediate prognosis with I. No significant financial relationships to disclose.